title: ¹⁸F-FDG PET/CT imaging of the pancreas: spectrum of diseases.
abstract: Since the introduction of integrated positron emission tomography-computed tomography (PET/CT), it has a great impact on the field of oncology. Comparing to other conventional scanners, only PET/CT is capable of providing important information on accurate detecting, staging/restaging, and post-therapeutic monitoring of many cancers. Many studies have demonstrated that PET/CT changes the management in approximately 30% of all cancer patients. Because 2-((18)F)-fluoro-2-deoxy-D-glucose (FDG) is a nonspecific tracer, understanding the PET/CT limitations and pitfalls for various pancreatic conditions can lead to more accurate interpretation of PET/CT images, which ultimately would impact patient care. As a result, it is important for radiologists and other clinicians to familiarize themselves with a wide spectrum of pancreatic PET/CT findings simulating cancer from benign entities.
authors.affiliation: Department of Gastroenterology and Hepatology, Mayo Clinic Arizona, Scottsdale, AZ 85259, USA. vnguy01@gmail.com
authors.forename: Vien X
authors.initials: VX
authors.lastname: Nguyen
authors.forename: Cuong C
authors.initials: CC
authors.lastname: Nguyen
authors.forename: Ba D
authors.initials: BD
authors.lastname: Nguyen
mesh_terms: D000230:Adenocarcinoma / Q000000981:diagnostic imaging / Q000473:pathology; D019788:Fluorodeoxyglucose F18; D006801:Humans; D008991:Monitoring, Physiologic / Q000379:methods; D064847:Multimodal Imaging / Q000379:methods*; D009362:Neoplasm Metastasis; D009367:Neoplasm Staging / Q000379:methods; D010179:Pancreas / Q000000981:diagnostic imaging*; D010182:Pancreatic Diseases / Q000145:classification / Q000000981:diagnostic imaging*; D010190:Pancreatic Neoplasms / Q000000981:diagnostic imaging / Q000473:pathology; D049268:Positron-Emission Tomography; D014057:Tomography, X-Ray Computed
chemical_list: D019788:Fluorodeoxyglucose F18